Korro Bio Inc
KRRO33.840USD
+1.270+3.90%
Fechamento 11/07, 16:00（ET）Cotações atrasadas em 15 min
317.79MValor de mercado
PerdaP/L TTM
Mais detalhes de Korro Bio Inc Empresa
Korro Bio, Inc. is a biopharmaceutical company. The Company discovers, develops, and commercializes genetic medicines based on editing ribonucleic acid (RNA), enabling treatment of both rare and highly prevalent diseases. The Company is generating a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, it is expanding the reach of genetic medicines. Its Oligonucleotide Promoted Editing of RNA (OPERA) is a foundational platform for RNA editing, which is designed to edit RNA in vivo by delivering an oligonucleotide guide that can target specific RNA sequences. The Company’s first development candidate, KRRO-110, is in development as a potential treatment for Alpha-1 Antitrypsin Deficiency (AATD), that has the potential to be disease-modifying and provide a differentiated therapeutic option.
Informações de Korro Bio Inc
Código da empresaKRRO
Nome da EmpresaKorro Bio Inc
Data de listagemOct 03, 2019
CEODr. Ram Aiyar, Ph.D.
Número de funcionários104
Tipo de títulosOrdinary Share
Fim do ano fiscalOct 03
EndereçoOne Kendall Square. Building 600-700
CidadeCAMBRIDGE
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal02139
Telefone16174681999
Sitehttps://www.korrobio.com/
Código da empresaKRRO
Data de listagemOct 03, 2019
CEODr. Ram Aiyar, Ph.D.
Executivos da empresa Korro Bio Inc
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Nessan Bermingham, Ph.D.
Dr. Nessan Bermingham, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
35.11K
--
Mr. Jeffrey (Jeff) Cerio, Pharm.D.
Mr. Jeffrey (Jeff) Cerio, Pharm.D.
Senior Vice President, General Counsel, Corporate Secretary
Senior Vice President, General Counsel, Corporate Secretary
--
--
Mr. Oliver Dolan
Mr. Oliver Dolan
Principal Accounting Officer
Principal Accounting Officer
--
--
Dr. Ali Behbahani, M.D.
Dr. Ali Behbahani, M.D.
Independent Director
Independent Director
--
--
Mr. Venkat Krishnamurthy, Ph.D.
Mr. Venkat Krishnamurthy, Ph.D.
Senior Vice President - Platform
Senior Vice President - Platform
--
--
Ms. Stephanie Engels
Ms. Stephanie Engels
Senior Vice President - People and Culture
Senior Vice President - People and Culture
--
--
Dr. Rachel Meyers, Ph.D.
Dr. Rachel Meyers, Ph.D.
Independent Director
Independent Director
--
--
Dr. Katharine (Kate) Knobil, M.D.
Dr. Katharine (Kate) Knobil, M.D.
Independent Director
Independent Director
--
--
Mr. Todd Chappell
Mr. Todd Chappell
Chief Operating Officer
Chief Operating Officer
--
--
Dr. Ram Aiyar, Ph.D.
Dr. Ram Aiyar, Ph.D.
President, Chief Executive Office (Principal Executive Officer), Interim Chief Financial Officer and Principal Financial Officer, Director
President, Chief Executive Office (Principal Executive Officer), Interim Chief Financial Officer and Principal Financial Officer, Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Nessan Bermingham, Ph.D.
Dr. Nessan Bermingham, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
35.11K
--
Mr. Jeffrey (Jeff) Cerio, Pharm.D.
Mr. Jeffrey (Jeff) Cerio, Pharm.D.
Senior Vice President, General Counsel, Corporate Secretary
Senior Vice President, General Counsel, Corporate Secretary
--
--
Mr. Oliver Dolan
Mr. Oliver Dolan
Principal Accounting Officer
Principal Accounting Officer
--
--
Dr. Ali Behbahani, M.D.
Dr. Ali Behbahani, M.D.
Independent Director
Independent Director
--
--
Mr. Venkat Krishnamurthy, Ph.D.
Mr. Venkat Krishnamurthy, Ph.D.
Senior Vice President - Platform
Senior Vice President - Platform
--
--
Ms. Stephanie Engels
Ms. Stephanie Engels
Senior Vice President - People and Culture
Senior Vice President - People and Culture
--
--
Detalhamento da receita
FY2025Q2
FY2025Q1
FY2024
Sem dados
Por RegiãoUSD
Nome
Receita
Proporção
United States
1.46M
0.00%
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: há 8 horas
Atualizado em: há 8 horas
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Atlas Venture
12.11%
New Enterprise Associates (NEA)
11.62%
Fidelity Management & Research Company LLC
6.81%
Driehaus Capital Management, LLC
6.19%
Platanus Investment LLC
5.75%
Outro
57.53%
Investidores
Investidores
Proporção
Atlas Venture
12.11%
New Enterprise Associates (NEA)
11.62%
Fidelity Management & Research Company LLC
6.81%
Driehaus Capital Management, LLC
6.19%
Platanus Investment LLC
5.75%
Outro
57.53%
Tipos de investidores
Investidores
Proporção
Investment Advisor
30.67%
Hedge Fund
27.09%
Venture Capital
23.72%
Investment Advisor/Hedge Fund
13.96%
Corporation
5.75%
Research Firm
1.37%
Individual Investor
0.42%
Private Equity
0.34%
Pension Fund
0.12%
Participação acionária institucional
Atualizado em: qua, 1 de out
Atualizado em: qua, 1 de out
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q3
186
9.14M
97.37%
-1.25M
2025Q2
186
10.38M
110.55%
-200.85K
2025Q1
189
10.53M
112.24%
-76.97K
2024Q4
194
10.26M
109.50%
+485.90K
2024Q3
177
9.16M
98.29%
-245.98K
2024Q2
167
9.06M
97.57%
+507.87K
2024Q1
179
7.52M
93.89%
+737.20K
2023Q4
198
7.18M
91.01%
+1.51M
2023Q3
223
264.10K
35.84%
-47.15K
2023Q2
235
150.53K
21.10%
-156.09K
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Atlas Venture
1.14M
12.11%
--
--
Jun 30, 2025
New Enterprise Associates (NEA)
1.09M
11.62%
--
--
Jun 30, 2025
Fidelity Management & Research Company LLC
639.22K
6.81%
-4.05K
-0.63%
Jun 30, 2025
Driehaus Capital Management, LLC
580.86K
6.19%
-1.59K
-0.27%
Jun 30, 2025
Platanus Investment LLC
540.16K
5.75%
--
--
Apr 15, 2025
Point72 Asset Management, L.P.
540.07K
5.75%
+19.18K
+3.68%
Jun 30, 2025
Cormorant Asset Management, LP
465.00K
4.95%
+84.70K
+22.27%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
423.16K
4.51%
+15.35K
+3.76%
Jun 30, 2025
Invus Public Equities Advisors, LLC
418.83K
4.46%
--
--
Jun 30, 2025
The Vanguard Group, Inc.
386.74K
4.12%
+4.94K
+1.29%
Jun 30, 2025
Ver Mais
ETFs Relacionados
Atualizado em: dom, 2 de nov
Atualizado em: dom, 2 de nov
Nome
Proporção
iShares Micro-Cap ETF
0.07%
Avantis US Small Cap Equity ETF
0.02%
iShares Russell 2000 Value ETF
0.02%
ProShares UltraPro Russell2000
0.01%
ProShares Hedge Replication ETF
0.01%
iShares Russell 2000 ETF
0.01%
Global X Russell 2000 ETF
0.01%
Proshares Ultra Russell 2000
0.01%
SPDR Portfolio MSCI Global Stock Market ETF
0%
Invesco Dorsey Wright SmallCap Momentum ETF
0%
Ver Mais
iShares Micro-Cap ETF
Proporção0.07%
Avantis US Small Cap Equity ETF
Proporção0.02%
iShares Russell 2000 Value ETF
Proporção0.02%
ProShares UltraPro Russell2000
Proporção0.01%
ProShares Hedge Replication ETF
Proporção0.01%
iShares Russell 2000 ETF
Proporção0.01%
Global X Russell 2000 ETF
Proporção0.01%
Proshares Ultra Russell 2000
Proporção0.01%
SPDR Portfolio MSCI Global Stock Market ETF
Proporção0%
Invesco Dorsey Wright SmallCap Momentum ETF
Proporção0%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Nov 03, 2023
Merger
50→1
Nov 03, 2023
Merger
50→1
Nov 03, 2023
Merger
50→1
Nov 03, 2023
Merger
50→1
Data
Tipo
Proporção
Nov 03, 2023
Merger
50→1
Nov 03, 2023
Merger
50→1
Nov 03, 2023
Merger
50→1
Nov 03, 2023
Merger
50→1
